ERBB2 and breast cancer: Lapatinib and gefitinib are theestablished inhibitor of HER2 that exert their activity by inhibiting the tyrosine kinase domain activation and have been approved for the management of BC and various other cancers [11,12].Inhibition of EGFR family arrests the cell cycle progression and stimulates the apoptosis in different cancer model [13,14,15].